NYSE:AVNS
AVANOS MEDICAL, INC.
A global leader in advanced surgical instruments offering the Avanos™ System and specialized endoscopic tools to hospitals and ambulatory surgery centers.
Key Metrics
Investment Thesis
Bull Case
AVANOS possesses a dominant market share in the laparoscopic instrument sector with a loyal customer base that creates a sustainable revenue stream even during periods of macroeconomic headwinds. The positive cash flow from operations provides a buffer to fund R&D and reduce debt, potentially setting the stage for future profitability once non-cash charges normalize. If the company can successfully launch new product categories or secure additional licensing deals, it could unlock significant value hidden within its current asset base.
Bear Case
The persistent double-digit net losses and a massive retained earnings deficit of over $779M indicate fundamental operational inefficiencies that have not been resolved despite years of revenue growth. High operating expenses relative to revenue suggest weak cost discipline, which is dangerous in the capital-intensive medical device industry where margins are under pressure. Investors should be wary of the company's reliance on a single product line and the potential for stock dilution if management needs to raise equity to cover ongoing cash burn.
About AVANOS MEDICAL, INC.
AVANOS Medical Inc. (NYSE: AVNS) is a global medical device manufacturer specializing in advanced surgical instruments, including the widely adopted Avanos™ System and specialized endoscopic tools. The company primarily serves hospitals, ambulatory surgery centers, and physician offices across North America and international markets with its high-precision laparoscopic and orthopedic product lines. By leveraging proprietary manufacturing technologies, AVNS aims to deliver innovative solutions that enhance surgical outcomes and operational efficiency for healthcare providers.
Analysis
Management Discussion
Despite a rebound in revenue to $701.2M in 2025, AVANOS continues to report substantial net losses of $-72.9M, with operating profit remaining negative at $-61.6M due to high general and administrative expenses totaling $315.6M. Cash flow from operations was positive at $74.7M, indicating strong core business liquidity, yet significant cash outflows for investing activities of $60.6M suggest ongoing capital deployment or acquisitions that have not yet generated returns. The company's ability to turnaround its profitability will depend on reducing operating expenses and successfully integrating any new product lines to improve margins.
Industry Overview
The global medical device industry is characterized by rapid innovation, stringent regulatory requirements, and high barriers to entry that favor established players with robust R&D pipelines. Market dynamics are increasingly influenced by value-based care models and hospital consolidation, which demand cost-effective yet high-quality surgical solutions from manufacturers like AVANOS. Competition is fierce among both large multinational corporations and niche innovators, driving a constant need for technological differentiation and strategic partnerships.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $820.0M | $673.3M | $687.8M | $701.2M |
| Cost of Revenue | $370.0M | $293.6M | $306.5M | $347.3M |
| Gross Profit | $450.0M | $379.7M | $381.3M | $353.9M |
| Operating Expenses | $376.0M | $375.5M | $777.5M | $415.5M |
| Operating Income | $74.0M | $4.2M | $-396.2M | $-61.6M |
| R&D | $30.6M | $27.2M | $26.2M | $23.3M |
| G&A | $341.9M | $335.0M | $318.5M | $315.6M |
| Stock-Based Comp | $15.9M | $15.8M | $13.8M | $12.6M |
| D&A | $47.7M | $46.1M | $45.5M | $38.9M |
| Depreciation | $22.0M | $19.2M | $20.3M | $19.7M |
| Amortization | $25.7M | $24.3M | $25.2M | $19.2M |
| Other OpEx | $3.5M | $13.3M | $432.8M | $76.6M |
| Non-Operating Income | $-8.8M | $-12.1M | $-7.1M | $-4.6M |
| Interest Expense | $10.0M | $15.0M | — | — |
| Interest Income | $1.2M | $2.9M | $5.1M | $3.2M |
| Pre-Tax Income | $65.2M | $-7.9M | $-403.3M | $-66.2M |
| Income Tax | $14.7M | $2.0M | $-17.0M | $6.7M |
| Continuing Ops | $50.5M | $-9.9M | $-386.3M | $-72.9M |
| Discontinued Ops | $0 | $-51.9M | $-5.8M | $0 |
| Net Income | $50.5M | $-61.8M | $-392.1M | $-72.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $50.5M | $-61.8M | $-392.1M | $-72.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $499.8M | $487.0M | $393.4M | $355.4M |
| Cash & Equivalents | $127.7M | $87.7M | $107.7M | $89.8M |
| Inventory | $190.3M | $163.2M | $138.8M | $148.0M |
| Prepaid Expenses | $13.9M | $28.8M | $14.1M | $13.8M |
| Other Current Assets | $167.9M | $207.3M | $132.8M | $103.8M |
| Long-Term Assets | $1.29B | $1.21B | $760.8M | $718.3M |
| PP&E (Net) | $163.9M | $117.2M | $110.7M | $113.4M |
| Intangibles | $251.0M | $239.5M | $112.3M | $117.8M |
| Goodwill | $819.4M | $796.1M | $455.6M | $394.9M |
| Operating Leases | $30.6M | $26.8M | $34.1M | $27.6M |
| Other LT Assets | $22.2M | $25.8M | $48.1M | $64.6M |
| Total Assets | $1.79B | $1.69B | $1.15B | $1.07B |
| Current Liabilities | $185.8M | $234.6M | $165.9M | $165.2M |
| Accounts Payable | $67.9M | $56.3M | $54.3M | $55.5M |
| Current Debt | $6.2M | $8.6M | $9.4M | $10.2M |
| Current Leases | $12.8M | $12.8M | $10.9M | $8.2M |
| Other Current Liab | $0 | $63.7M | $0 | $0 |
| Long-Term Liabilities | $309.9M | $221.5M | $159.8M | $130.3M |
| Long-Term Debt | $226.3M | — | — | — |
| LT Operating Leases | $34.7M | $28.3M | $24.6M | $20.4M |
| Other LT Liab | $48.9M | $193.2M | $135.2M | $109.9M |
| Total Liabilities | $495.7M | $456.1M | $325.7M | $295.5M |
| Shareholders' Equity | $1.29B | $1.24B | $828.5M | $778.2M |
| Paid-In Capital | $1.65B | $1.66B | $1.68B | $1.69B |
| Retained Earnings | $-253.1M | $-314.9M | $-707.0M | $-779.9M |
| AOCI | $-35.8M | $-27.0M | $-44.6M | $-32.0M |
| Total L&E | $1.79B | $1.69B | $1.15B | $1.07B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $50.5M | $-61.8M | $-392.1M | $-72.9M |
| Non-Cash Adjustments | $-40.5M | $160.4M | $538.7M | $192.4M |
| Working Capital Changes | $80.9M | $-66.2M | $-45.9M | $-44.8M |
| Cash from Operations | $90.9M | $32.4M | $100.7M | $74.7M |
| Cash from Investing | $-135.4M | $21.6M | $-27.5M | $-60.6M |
| Share Buybacks | $45.5M | $19.1M | $12.8M | $3.3M |
| Cash from Financing | $56.7M | $-94.2M | $-49.1M | $-37.0M |
| FX Effect | $-3.0M | $200.0K | $-4.1M | $5.0M |
| Net Change in Cash | $9.2M | $-40.0M | $20.0M | $-17.9M |
| Beginning Cash | $118.5M | $127.7M | $87.7M | $107.7M |
| Ending Cash | $127.7M | $87.7M | $107.7M | $89.8M |
Frequently Asked Questions
How does AVANOS MEDICAL, INC. make money?
The company's revenue is primarily driven by its core portfolio of laparoscopic and orthopedic surgical instruments, which includes the dominant Avanos™ System for minimally invasive procedures. Additional streams include sales of disposable medical devices, custom-engineered solutions for specialized surgeries, and ongoing royalties from strategic licensing agreements with external manufacturers.
What are the main risks for AVNS?
The company faces significant revenue concentration risk as a large portion of sales depends on a single flagship product, the Avanos™ System, making it vulnerable to competitive displacement or regulatory changes. Persistent net losses and a growing retained earnings deficit highlight challenges in scaling profitability despite high revenue generation. Dependence on third-party distributors and potential supply chain disruptions for raw materials could impact inventory levels and delivery timelines. Intense competition from large medical conglomerates and generic device manufacturers threatens long-term pricing power and market share.
What is AVNS's competitive advantage?
AVANOS holds a strong market position through its patented proprietary technologies that provide superior precision and ergonomics compared to generic alternatives. The company benefits from high switching costs within the hospital ecosystem due to established surgeon preferences and integrated workflow solutions that reduce operative time. Its vertically integrated manufacturing capabilities allow for consistent quality control and cost efficiency in producing complex surgical instruments.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.